Back to Search
Start Over
First dual AK/GSK-3β inhibitors endowed with antioxidant properties as multifunctional, potential neuroprotective agents.
- Source :
-
European journal of medicinal chemistry [Eur J Med Chem] 2017 Sep 29; Vol. 138, pp. 438-457. Date of Electronic Publication: 2017 Jun 09. - Publication Year :
- 2017
-
Abstract
- The manuscript deals with the design, synthesis and biological evaluation of novel benzoxazinone-based and indole-based compounds as multifunctional neuroprotective agents. These compounds inhibit human adenosine kinase (hAK) and human glycogen synthase kinase 3 beta (hGSK-3β) enzymes. Computational analysis based on a molecular docking approach underlined the potential structural requirements for simultaneously targeting both proteins' allosteric sites. In silico hints drove the synthesis of appropriately decorated benzoxazinones and indoles (5a-s, and 6a-c) and biochemical analysis revealed their behavior as allosteric inhibitors of hGSK-3β. For both our hit 4 and the best compounds of the series (5c,l and 6b) the potential antioxidant profile was assessed in human neuroblastoma cell lines (IMR 32, undifferentiated and neuronal differentiated), by evaluating the protective effect of selected compounds against H <subscript>2</subscript> O <subscript>2</subscript> cytotoxicity and reactive oxygen species (ROS) production. Results showed a strong efficacy of the tested compounds, even at the lower doses, in counteracting the induced oxidative stress (50 μM of H <subscript>2</subscript> O <subscript>2</subscript> ) and in preventing ROS formation. In addition, the tested compounds did not show any cytotoxic effect determined by the LDH release, at the concentration range analyzed (from 0.1 to 50 μM). This study allowed the identification of compound 5l, as the first dual hAK/hGSK-3β inhibitor reported to date. Compound 5l, which behaves as an effective antioxidant, holds promise for the development of new series of potential therapeutic agents for the treatment of neurodegenerative diseases characterized by an innovative pharmacological profile.<br /> (Copyright © 2017 Elsevier Masson SAS. All rights reserved.)
- Subjects :
- Adenosine Kinase metabolism
Antioxidants chemical synthesis
Antioxidants chemistry
Cell Line, Tumor
Dose-Response Relationship, Drug
Glycogen Synthase Kinase 3 beta metabolism
Humans
Hydrogen Peroxide antagonists & inhibitors
Hydrogen Peroxide pharmacology
Molecular Structure
Neuroblastoma pathology
Neuroprotective Agents chemical synthesis
Neuroprotective Agents chemistry
Oxidative Stress drug effects
Protein Kinase Inhibitors chemical synthesis
Protein Kinase Inhibitors chemistry
Reactive Oxygen Species metabolism
Structure-Activity Relationship
Adenosine Kinase antagonists & inhibitors
Antioxidants pharmacology
Glycogen Synthase Kinase 3 beta antagonists & inhibitors
Neuroblastoma metabolism
Neuroprotective Agents pharmacology
Protein Kinase Inhibitors pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1768-3254
- Volume :
- 138
- Database :
- MEDLINE
- Journal :
- European journal of medicinal chemistry
- Publication Type :
- Academic Journal
- Accession number :
- 28689095
- Full Text :
- https://doi.org/10.1016/j.ejmech.2017.06.017